Copy to clipboard 
Demetra, provider of bone cements, spacers and biomaterials for orthopedic applications and orthopedic infection control, completed a strategic asset purchase from Next Science, developer of technologies designed to reduce the impact of infections in human health.
The addition of these technologies will allow Demetra to provide a portfolio of infection management solutions. Osartis, a Demetra company, will take ownership of these assets globally. Other companies under the Demetra umbrella include Tecres, GetSet Surgical, OrthoFundamentals (now Demetra Spine) and OsteoRemedies.
Harry Hall IV, Managing Director and CEO of Next Science, stated: “This sale ensures the innovations developed by our Next Science team will reach more patients than ever before. With Demetra’s international presence and ability to scale, the technologies we created are well positioned to advance infection management and make a lasting difference for patients and clinicians worldwide.”
“By acquiring Next Science’s cutting-edge technologies, we take another decisive step in expanding the Demetra PJI portfolio and beyond. This move strengthens our long-standing collaboration with healthcare professionals and reaffirms our purpose-driven approach, bringing transformative solutions to improve lives across the globe,” commented Michele Perrino, CEO of Demetra.
Chris Hughes, President & CEO of OsteoRemedies further commented, “Next Science provides OsteoRemedies with additional data driven, yet simple solutions to offer our surgeons and patients. As we continue to build on our market leading position for infection management, I am excited about how well this matches our Vision.”
Source: Demetra S.p.A.
Demetra, provider of bone cements, spacers and biomaterials for orthopedic applications and orthopedic infection control, completed a strategic asset purchase from Next Science, developer of technologies designed to reduce the impact of infections in human health.
The addition of these technologies will allow Demetra to provide a portfolio of...
Demetra, provider of bone cements, spacers and biomaterials for orthopedic applications and orthopedic infection control, completed a strategic asset purchase from Next Science, developer of technologies designed to reduce the impact of infections in human health.
The addition of these technologies will allow Demetra to provide a portfolio of infection management solutions. Osartis, a Demetra company, will take ownership of these assets globally. Other companies under the Demetra umbrella include Tecres, GetSet Surgical, OrthoFundamentals (now Demetra Spine) and OsteoRemedies.
Harry Hall IV, Managing Director and CEO of Next Science, stated: “This sale ensures the innovations developed by our Next Science team will reach more patients than ever before. With Demetra’s international presence and ability to scale, the technologies we created are well positioned to advance infection management and make a lasting difference for patients and clinicians worldwide.”
“By acquiring Next Science’s cutting-edge technologies, we take another decisive step in expanding the Demetra PJI portfolio and beyond. This move strengthens our long-standing collaboration with healthcare professionals and reaffirms our purpose-driven approach, bringing transformative solutions to improve lives across the globe,” commented Michele Perrino, CEO of Demetra.
Chris Hughes, President & CEO of OsteoRemedies further commented, “Next Science provides OsteoRemedies with additional data driven, yet simple solutions to offer our surgeons and patients. As we continue to build on our market leading position for infection management, I am excited about how well this matches our Vision.”
Source: Demetra S.p.A.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
